{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T22:17:37Z","timestamp":1790115457837,"version":"4.0.1"},"reference-count":90,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2022,10]]},"DOI":"10.1016\/j.clml.2022.07.010","type":"journal-article","created":{"date-parts":[[2022,7,20]],"date-time":"2022-07-20T16:47:35Z","timestamp":1658335655000},"page":"718-725","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"title":["SOHO State of the Art Updates and Next Questions | Novel Approaches to Pediatric T-cell ALL and T-Lymphoblastic Lymphoma"],"prefix":"10.1016","volume":"22","author":[{"given":"Ryan J","family":"Summers","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7373-8987","authenticated-orcid":false,"given":"David T","family":"Teachey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2022.07.010_bib0001","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1182\/blood.2019001557","article-title":"How I treat newly diagnosed T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma in children","volume":"135","author":"Teachey","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.clml.2022.07.010_bib0002","doi-asserted-by":"crossref","first-page":"e142","DOI":"10.1016\/S1470-2045(19)30031-2","article-title":"Comparative features and outcomes between paediatric T-cell and B-cell acute lymphoblastic leukaemia","volume":"20","author":"Teachey","year":"2019","journal-title":"The Lancet Oncol"},{"key":"10.1016\/j.clml.2022.07.010_bib0003","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1111\/bjh.15793","article-title":"Lymphoblastic lymphoma in children and adolescents: review of current challenges and future opportunities","volume":"185","author":"Burkhardt","year":"2019","journal-title":"British J Hematol"},{"key":"10.1016\/j.clml.2022.07.010_bib0004","doi-asserted-by":"crossref","first-page":"3062","DOI":"10.1200\/JCO.20.00531","article-title":"Successful outcomes of newly diagnosed T lymphoblastic lymphoma: results from children's oncology group AALL0434","volume":"38","author":"Hayashi","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2022.07.010_bib0005","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1016\/S1470-2045(14)70243-8","article-title":"Augmented post-remission therapy for a minimal residual disease-defined high-risk subgroup of children and young people with clinical standard-risk and intermediate-risk acute lymphoblastic leukaemia (UKALL 2003): a randomised controlled trial","volume":"15","author":"Vora","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clml.2022.07.010_bib0006","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1200\/JCO.2012.43.2070","volume":"31","author":"Vrooman","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2022.07.010_bib0007","doi-asserted-by":"crossref","first-page":"2926","DOI":"10.1200\/JCO.2018.77.7250","article-title":"Improved survival for children and young adults with T-lineage acute lymphoblastic leukemia: results from the children's oncology group AALL0434 methotrexate randomization","volume":"36","author":"Winter","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2022.07.010_bib0008","doi-asserted-by":"crossref","first-page":"2101","DOI":"10.1182\/blood-2015-09-670729","article-title":"Dexamethasone vs. prednisone in induction treatment of pediatric ALL: results of the randomized trial AIEOP-BFM ALL 2000","volume":"127","author":"Moricke","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.clml.2022.07.010_bib0009","doi-asserted-by":"crossref","first-page":"2591","DOI":"10.1200\/JCO.2015.64.6364","article-title":"Successful therapy reduction and intensification for childhood acute lymphoblastic leukemia based on minimal residual disease monitoring: study ALL10 from the dutch childhood oncology group","volume":"34","author":"Pieters","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2022.07.010_bib0010","doi-asserted-by":"crossref","first-page":"2730","DOI":"10.1056\/NEJMoa0900386","article-title":"Treating childhood acute lymphoblastic leukemia without cranial irradiation","volume":"360","author":"Pui","year":"2009","journal-title":"The New England J Med"},{"key":"10.1016\/j.clml.2022.07.010_bib0011","doi-asserted-by":"crossref","first-page":"2086","DOI":"10.3324\/haematol.2015.139162","article-title":"Results and conclusions of the European Intergroup EURO-LB02 trial in children and adolescents with lymphoblastic lymphoma","volume":"102","author":"Landmann","year":"2017","journal-title":"Hematologica"},{"key":"10.1016\/j.clml.2022.07.010_bib0012","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1002\/pbc.24149","article-title":"Outcome of newly diagnosed children and adolescents with localized lymphoblastic lymphoma treated on Children's Oncology Group trial A5971: a report from the Children's Oncology Group","volume":"59","author":"Termuhlen","year":"2012","journal-title":"Pediatric Blood & Can"},{"key":"10.1016\/j.clml.2022.07.010_bib0013","doi-asserted-by":"crossref","first-page":"3282","DOI":"10.1200\/JCO.20.00256","article-title":"Children's oncology group AALL0434: a phase III randomized clinical trial testing nelarabine in newly diagnosed T-cell acute lymphoblastic leukemia","volume":"38","author":"Dunsmore","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2022.07.010_bib0014","first-page":"416","article-title":"Intensive ALL-type therapy without local radiotherapy provides a 90% event-free survival for children with T-cell lymphoblastic lymphoma: a BFM group report","volume":"95","author":"Reiter","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.clml.2022.07.010_bib0015","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1016\/j.ejca.2008.02.011","article-title":"Treatment of childhood T-cell lymphoblastic lymphoma according to the strategy for acute lymphoblastic leukaemia, without radiotherapy: long term results of the EORTC CLG 58881 trial","volume":"44","author":"Uyttebroeck","year":"2008","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.clml.2022.07.010_bib0016","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1007\/s10147-008-0771-5","article-title":"Intensive chemotherapy improved treatment outcome for Chinese children and adolescents with lymphoblastic lymphoma","volume":"13","author":"Sun","year":"2008","journal-title":"Int J Clin Oncol"},{"key":"10.1016\/j.clml.2022.07.010_bib0017","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1038\/leu.2008.400","article-title":"Effective treatment of advanced-stage childhood lymphoblastic lymphoma without prophylactic cranial irradiation: results of St Jude NHL13 study","volume":"23","author":"Sandlund","year":"2009","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2022.07.010_bib0018","doi-asserted-by":"crossref","first-page":"3153","DOI":"10.1182\/blood-2012-12-474148","article-title":"Incidence and prognostic relevance of genetic variations in T-cell lymphoblastic lymphoma in childhood and adolescence","volume":"121","author":"Bonn","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.clml.2022.07.010_bib0019","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1002\/gcc.20924","article-title":"T-cell lymphoblastic lymphoma shows differences and similarities with T-cell acute lymphoblastic leukemia by genomic and gene expression analyses","volume":"50","author":"Basso","year":"2011","journal-title":"Genes, Chromosomes and Can"},{"key":"10.1016\/j.clml.2022.07.010_bib0020","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","article-title":"The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia","volume":"127","author":"Arber","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.clml.2022.07.010_bib0021","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1182\/asheducation-2016.1.580","article-title":"T-cell acute lymphoblastic leukemia","volume":"1","author":"Raetz","year":"2016","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"10.1016\/j.clml.2022.07.010_bib0022","doi-asserted-by":"crossref","first-page":"3377","DOI":"10.1200\/JCO.19.01692","article-title":"Improved CNS control of childhood acute lymphoblastic leukemia without cranial irradiation: St Jude total therapy study 16","volume":"37","author":"Jeha","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2022.07.010_bib0023","doi-asserted-by":"crossref","first-page":"986","DOI":"10.3324\/haematol.2018.204545","article-title":"Replacing cyclophosphamide\/cytarabine\/mercaptopurine with cyclophosphamide\/etoposide during consolidation\/delayed intensification does not improve outcome for pediatric B-cell acute lymphoblastic leukemia: a report from the COG","volume":"104","author":"Burke","year":"2019","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2022.07.010_bib0024","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1002\/cncr.31099","article-title":"Toxicity associated with intensive postinduction therapy incorporating clofarabine in the very high-risk stratum of patients with newly diagnosed high-risk B-lymphoblastic leukemia: a report from the children's oncology group study AALL1131","volume":"124","author":"Salzer","year":"2018","journal-title":"Cancer"},{"key":"10.1016\/j.clml.2022.07.010_bib0025","doi-asserted-by":"crossref","first-page":"2628","DOI":"10.1200\/JCO.19.02892","article-title":"Impact of intrathecal triple therapy versus intrathecal methotrexate on disease-free survival for high-risk B-lymphoblastic leukemia: children's oncology group study AALL1131","volume":"38","author":"Salzer","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2022.07.010_bib0026","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.1182\/blood-2011-03-338707","article-title":"Late MRD response determines relapse risk overall and in subsets of childhood T-cell ALL: results of the AIEOP-BFM-ALL 2000 study","volume":"118","author":"Schrappe","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.clml.2022.07.010_bib0027","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1182\/blood.V124.21.1.1","volume":"124","author":"Wood","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.clml.2022.07.010_bib0028","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1182\/blood-2017-04-778829","article-title":"Oncogenetic mutations combined with MRD improve outcome prediction in pediatric T-cell acute lymphoblastic leukemia","volume":"131","author":"Petit","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.clml.2022.07.010_bib0029","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1038\/leu.2015.206","article-title":"Impact of PTEN abnormalities on outcome in pediatric patients with T-cell acute lymphoblastic leukemia treated on the MRC UKALL2003 trial","volume":"30","author":"Jenkinson","year":"2016","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2022.07.010_bib0030","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1038\/ng.3909","article-title":"The genomic landscape of pediatric and young adult T-lineage acute lymphoblastic leukemia","volume":"49","author":"Liu","year":"2017","journal-title":"Nature Genetics"},{"key":"10.1016\/j.clml.2022.07.010_bib0031","doi-asserted-by":"crossref","first-page":"3816","DOI":"10.1200\/JCO.2010.28.3390","article-title":"Absence of biallelic TCRgamma deletion predicts early treatment failure in pediatric T-cell acute lymphoblastic leukemia","volume":"28","author":"Gutierrez","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2022.07.010_bib0032","doi-asserted-by":"crossref","first-page":"e288","DOI":"10.3324\/haematol.2017.185801","article-title":"Prognostic impact of the absence of biallelic deletion at the TRG locus for pediatric patients with T-cell acute lymphoblastic leukemia treated on the Medical Research Council UK Acute Lymphoblastic Leukemia 2003 trial","volume":"103","author":"Farah","year":"2018","journal-title":"Hematologica"},{"key":"10.1016\/j.clml.2022.07.010_bib0033","doi-asserted-by":"crossref","first-page":"928","DOI":"10.3324\/haematol.2012.073585","article-title":"NOTCH1 activation clinically antagonizes the unfavorable effect of PTEN inactivation in BFM-treated children with precursor T-cell acute lymphoblastic leukemia","volume":"98","author":"Bandapalli","year":"2013","journal-title":"Hematologica"},{"key":"10.1016\/j.clml.2022.07.010_bib0034","doi-asserted-by":"crossref","first-page":"2594","DOI":"10.1038\/leu.2017.157","article-title":"Age-related clinical and biological features of PTEN abnormalities in T-cell acute lymphoblastic leukaemia","volume":"31","author":"Tesio","year":"2017","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2022.07.010_bib0035","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1111\/j.1365-2141.2009.07607.x","article-title":"FBXW7andNOTCH1mutations in childhood T cell acute lymphoblastic leukaemia and T cell non-Hodgkin lymphoma","volume":"145","author":"Park","year":"2009","journal-title":"British J Hematology"},{"key":"10.1016\/j.clml.2022.07.010_bib0036","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1126\/science.1259037","article-title":"An oncogenic super-enhancer formed through somatic mutation of a noncoding intergenic element","volume":"346","author":"Mansour","year":"2014","journal-title":"Science"},{"key":"10.1016\/j.clml.2022.07.010_bib0037","doi-asserted-by":"crossref","first-page":"3221","DOI":"10.1182\/blood-2016-09-742148","article-title":"Activation of the LMO2 oncogene through a somatically acquired neomorphic promoter in T-cell acute lymphoblastic leukemia","volume":"129","author":"Rahman","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.clml.2022.07.010_bib0038","doi-asserted-by":"crossref","first-page":"3264","DOI":"10.1182\/blood-2017-03-771162","article-title":"Whole-genome noncoding sequence analysis in T-cell acute lymphoblastic leukemia identifies oncogene enhancer mutations","volume":"129","author":"Hu","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.clml.2022.07.010_bib0039","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1097\/01.HS9.0000843304.00278.87","article-title":"Comprehensive genome characterization reveals new subtypes and mechanisms of oncongene deregulation in childhood T-ALL","volume":"6","author":"P\u00f6l\u00f6nen","year":"2022","journal-title":"HemaSphere"},{"key":"10.1016\/j.clml.2022.07.010_bib0040","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/S1470-2045(08)70314-0","article-title":"Early T-cell precursor leukaemia: a subtype of very high-risk acute lymphoblastic leukaemia","volume":"10","author":"Coustan-Smith","year":"2009","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clml.2022.07.010_bib0041","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1111\/j.1365-2141.2011.08955.x","article-title":"Clinical significance of early T-cell precursor acute lymphoblastic leukaemia: results of the Tokyo children's cancer study group study L99-15","volume":"156","author":"Inukai","year":"2012","journal-title":"Br J Hematol"},{"key":"10.1016\/j.clml.2022.07.010_bib0042","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1007\/s11684-012-0224-4","article-title":"Early T-cell precursor leukemia: a subtype of high risk childhood acute lymphoblastic leukemia","volume":"6","author":"Ma","year":"2012","journal-title":"Front Med"},{"key":"10.1016\/j.clml.2022.07.010_bib0043","doi-asserted-by":"crossref","first-page":"e80","DOI":"10.1016\/S2352-3026(15)00254-9","article-title":"Early T-cell precursor acute lymphoblastic leukaemia in children treated in AIEOP centres with AIEOP-BFM protocols: a retrospective analysis","volume":"3","author":"Conter","year":"2016","journal-title":"The Lancet Hematol"},{"key":"10.1016\/j.clml.2022.07.010_bib0044","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1111\/bjh.12882","article-title":"Outcome for children and young people with Early T-cell precursor acute lymphoblastic leukaemia treated on a contemporary protocol, UKALL 2003","volume":"166","author":"Patrick","year":"2014","journal-title":"Br J Hematol"},{"key":"10.1016\/j.clml.2022.07.010_bib0045","doi-asserted-by":"crossref","first-page":"94","DOI":"10.3324\/haematol.2013.090233","article-title":"Immature MEF2C-dysregulated T-cell leukemia patients have an early T-cell precursor acute lymphoblastic leukemia gene signature and typically have non-rearranged T-cell receptors","volume":"99","author":"Zuurbier","year":"2014","journal-title":"Hematologica"},{"key":"10.1016\/j.clml.2022.07.010_bib0046","doi-asserted-by":"crossref","first-page":"e28719","DOI":"10.1002\/pbc.28719","article-title":"Identification of prognostic factors in childhood T-cell acute lymphoblastic leukemia: Results from DFCI ALL Consortium Protocols 05-001 and 11-001","volume":"68","author":"Burns","year":"2021","journal-title":"Pediatr Blood & Can"},{"key":"10.1016\/j.clml.2022.07.010_bib0047","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1111\/bjh.14017","article-title":"Current status and future directions of T-lymphoblastic lymphoma in children and adolescents","volume":"173","author":"Burkhardt","year":"2016","journal-title":"British J Hematol"},{"key":"10.1016\/j.clml.2022.07.010_bib0048","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1111\/bjh.12460","article-title":"Disseminated lymphoblastic lymphoma in children and adolescents: results of the COG A5971 trial: a report from the Children's Oncology Group","volume":"162","author":"Termuhlen","year":"2013","journal-title":"Br J Hematol"},{"key":"10.1016\/j.clml.2022.07.010_bib0049","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1002\/pbc.21823","article-title":"Bone marrow minimal disseminated disease (MDD) and minimal residual disease (MRD) in childhood T-cell lymphoblastic lymphoma stage III, detected by flow cytometry (FC) and real-time quantitative polymerase chain reaction (RQ-PCR)","volume":"52","author":"Stark","year":"2009","journal-title":"Pediatr Blood & Can"},{"key":"10.1016\/j.clml.2022.07.010_bib0050","doi-asserted-by":"crossref","first-page":"1906","DOI":"10.1002\/pbc.25607","article-title":"Detection and role of minimal disseminated disease in children with lymphoblastic lymphoma: The AIEOP experience","volume":"62","author":"Mussolin","year":"2015","journal-title":"Pediatr Blood Can"},{"key":"10.1016\/j.clml.2022.07.010_bib0051","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.1200\/JCO.21.02678","article-title":"Children\u2019s oncology group trial AALL1231: a phase III clinical trial testing bortezomib in newly diagnosed T-cell acute lymphoblastic leukemia and lymphoma","volume":"40","author":"Teachey","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2022.07.010_bib0052","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1038\/sj.leu.2404275","article-title":"Loss of heterozygosity on chromosome 6q14\u2013q24 is associated with poor outcome in children and adolescents with T-cell lymphoblastic lymphoma","volume":"20","author":"Burkhardt","year":"2006","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2022.07.010_bib0053","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1080\/10428190701824551","article-title":"Pediatric precursor T lymphoblastic leukemia and lymphoblastic lymphoma: Differences in the common regions with loss of heterozygosity at chromosome 6q and their prognostic impact","volume":"49","author":"Burkhardt","year":"2008","journal-title":"Leukemia & Lymphoma"},{"key":"10.1016\/j.clml.2022.07.010_bib0054","doi-asserted-by":"crossref","first-page":"2347","DOI":"10.1182\/blood.2020005381","article-title":"Integrative genomic analysis of pediatric T-cell lymphoblastic lymphoma reveals candidates of clinical significance","volume":"137","author":"Khanam","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.clml.2022.07.010_bib0055","doi-asserted-by":"crossref","first-page":"1966","DOI":"10.1200\/JCO.2011.39.7661","article-title":"Clinical Impact of NOTCH1and\/or FBXW7Mutations, FLASHDeletion, and TCRStatus in Pediatric T-Cell Lymphoblastic Lymphoma","volume":"30","author":"Callens","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2022.07.010_bib0056","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1038\/leu.2015.203","article-title":"Proposal of a genetic classifier for risk group stratification in pediatric T-cell lymphoblastic lymphoma reveals differences from adult T-cell lymphoblastic leukemia","volume":"30","author":"Balbach","year":"2016","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2022.07.010_bib0057","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1111\/bjh.15919","article-title":"Bortezomib reinduction chemotherapy in high-risk ALL in first relapse: a report from the Children's Oncology Group","volume":"186","author":"Horton","year":"2019","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2022.07.010_bib0058","doi-asserted-by":"crossref","first-page":"3376","DOI":"10.1200\/JCO.2005.03.426","article-title":"Phase II study of nelarabine (compound 506U78) in children and young adults with refractory T-cell malignancies: a report from the Children's Oncology Group","volume":"23","author":"Berg","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2022.07.010_bib0059","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1038\/nm.1900","article-title":"Gamma-secretase inhibitors reverse glucocorticoid resistance in T cell acute lymphoblastic leukemia","volume":"15","author":"Real","year":"2009","journal-title":"Nat Med"},{"key":"10.1016\/j.clml.2022.07.010_bib0060","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1182\/blood-2014-06-580480","article-title":"Efficacy of JAK\/STAT pathway inhibition in murine xenograft models of early T-cell precursor (ETP) acute lymphoblastic leukemia","volume":"125","author":"Maude","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.clml.2022.07.010_bib0061","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1172\/JCI130189","article-title":"Glucocorticoids paradoxically facilitate steroid resistance in T cell acute lymphoblastic leukemias and thymocytes","volume":"130","author":"Meyer","year":"2020","journal-title":"J Clin Invest"},{"key":"10.1016\/j.clml.2022.07.010_bib0062","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1016\/j.ccr.2012.09.016","article-title":"Therapeutic targeting of the cyclin D3:CDK4\/6 complex in T cell leukemia","volume":"22","author":"Sawai","year":"2012","journal-title":"Cancer Cell"},{"key":"10.1016\/j.clml.2022.07.010_bib0063","first-page":"20","article-title":"Safety of palbociclib in combination with chemotherapy in children and young adult patients with relapsed\/refractory acute lymphoblastic leukemia and lymphoma: a Children\u2019s Oncology Group pilot study","volume":"136","author":"Raetz","year":"2020","journal-title":"Blood, ASH Annual Meeting Abstracts,"},{"key":"10.1016\/j.clml.2022.07.010_bib0064","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1158\/1078-0432.CCR-15-2869","article-title":"Synergistic drug combinations with a CDK4\/6 inhibitor in T-cell acute lymphoblastic leukemia","volume":"23","author":"Pikman","year":"2017","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clml.2022.07.010_bib0065","doi-asserted-by":"crossref","first-page":"e27062","DOI":"10.1002\/pbc.27062","article-title":"Phase I trial of the mTOR inhibitor everolimus in combination with multi-agent chemotherapy in relapsed childhood acute lymphoblastic leukemia","volume":"65","author":"Place","year":"2018","journal-title":"Pediatr Blood Can"},{"key":"10.1016\/j.clml.2022.07.010_bib0066","doi-asserted-by":"crossref","first-page":"e17","DOI":"10.3324\/haematol.2018.199257","article-title":"Pre-clinical evaluation of second generation PIM inhibitors for the treatment of T-cell acute lymphoblastic leukemia and lymphoma","volume":"104","author":"De Smedt","year":"2019","journal-title":"Hematologica"},{"key":"10.1016\/j.clml.2022.07.010_bib0067","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1158\/2159-8290.CD-14-0353","article-title":"Maturation stage of T-cell acute lymphoblastic leukemia determines BCL-2 versus BCL-XL dependence and sensitivity to ABT-199","volume":"4","author":"Chonghaile","year":"2014","journal-title":"Cancer Discov"},{"key":"10.1016\/j.clml.2022.07.010_bib0068","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1200\/JCO.2011.34.7898","article-title":"Substantial susceptibility of chronic lymphocytic leukemia to BCL2 inhibition: results of a phase I study of navitoclax in patients with relapsed or refractory disease","volume":"30","author":"Roberts","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2022.07.010_bib0069","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1016\/S1470-2045(10)70261-8","article-title":"Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase I dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity","volume":"11","author":"Wilson","year":"2010","journal-title":"The Lancet Oncol"},{"key":"10.1016\/j.clml.2022.07.010_bib0070","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1158\/2159-8290.CD-20-1465","article-title":"Venetoclax and navitoclax in combination with chemotherapy in patients with relapsed or refractory acute lymphoblastic leukemia and lymphoblastic lymphoma","volume":"11","author":"Pullarkat","year":"2021","journal-title":"Cancer Discov"},{"key":"10.1016\/j.clml.2022.07.010_bib0071","doi-asserted-by":"crossref","first-page":"e26","DOI":"10.1182\/blood-2016-09-738070","article-title":"Ex vivo drug response profiling detects recurrent sensitivity patterns in drug-resistant acute lymphoblastic leukemia","volume":"129","author":"Frismantas","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.clml.2022.07.010_bib0072","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1038\/s43018-020-00167-4","article-title":"Network-based systems pharmacology reveals heterogeneity in LCK and BCL2 signaling and therapeutic sensitivity of T-cell acute lymphoblastic leukemia","volume":"2","author":"Gocho","year":"2021","journal-title":"Nature Can"},{"key":"10.1016\/j.clml.2022.07.010_bib0073","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1080\/1744666X.2020.1732819","article-title":"Harnessing immunotherapy for pediatric T-cell malignancies","volume":"16","author":"Diorio","year":"2020","journal-title":"Expert Rev Clin Immunol"},{"key":"10.1016\/j.clml.2022.07.010_bib0074","doi-asserted-by":"crossref","first-page":"4665","DOI":"10.1182\/bloodadvances.2020002502","article-title":"CD1a is rarely expressed in pediatric or adult relapsed\/refractory T-ALL: implications for immunotherapy","volume":"4","author":"Leong","year":"2020","journal-title":"Blood Adv"},{"key":"10.1016\/j.clml.2022.07.010_bib0075","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1182\/blood-2017-07-794214","article-title":"Preclinical efficacy of daratumumab in T-cell acute lymphoblastic leukemia (T-ALL)","volume":"131","author":"Bride","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.clml.2022.07.010_bib0076","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1182\/blood.2019000904","article-title":"Daratumumab eradicates minimal residual disease in a preclinical model of pediatric T-cell acute lymphoblastic leukemia","volume":"134","author":"Vogiatzi","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.clml.2022.07.010_bib0077","doi-asserted-by":"crossref","first-page":"10001","DOI":"10.1200\/JCO.2022.40.16_suppl.10001","article-title":"Efficacy and safety of daratumumab (DARA) in pediatric and young adult patients (pts) with relapsed\/refractory T-cell acute lymphoblastic leukemia (ALL) or lymphoblastic lymphoma (LL): Results from the phase II DELPHINUS study","volume":"40","author":"Hogan","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2022.07.010_bib0078","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1097\/01.HS9.0000844328.90982.61","article-title":"Efficacy and safety of daratumumab in pediatric and young adult patients with relapsed\/refractory T-cell acute lymphoblastic leukemia or lymphoblastic lymphoma: results from phase II Delphinus study","volume":"6","author":"Vora","year":"2022","journal-title":"HemaSphere"},{"key":"10.1016\/j.clml.2022.07.010_bib0079","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1002\/pbc.20550","article-title":"Gene expression profiling reveals intrinsic differences between T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma","volume":"47","author":"Raetz","year":"2006","journal-title":"Pediatr Blood & Can"},{"key":"10.1016\/j.clml.2022.07.010_bib0080","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1158\/0008-5472.CAN-10-2238","article-title":"Therapeutic antibody targeting of CD47 eliminates human acute lymphoblastic leukemia","volume":"71","author":"Chao","year":"2011","journal-title":"Can Res"},{"key":"10.1016\/j.clml.2022.07.010_bib0081","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1038\/s41419-018-0601-2","article-title":"CD47-ligation induced cell death in T-acute lymphoblastic leukemia","volume":"9","author":"Leclair","year":"2018","journal-title":"Cell Death & Disease"},{"key":"10.1016\/j.clml.2022.07.010_bib0082","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/s12943-018-0768-2","article-title":"MIR-708 promotes phagocytosis to eradicate T-ALL cells by targeting CD47","volume":"17","author":"Huang","year":"2018","journal-title":"Molecular Cancer"},{"key":"10.1016\/j.clml.2022.07.010_bib0083","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1182\/blood.2021014485","article-title":"Combining daratumumab with CD47 blockade prolongs survival in preclinical models of pediatric T-ALL","volume":"140","author":"M\u00fcller","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.clml.2022.07.010_bib0084","doi-asserted-by":"crossref","DOI":"10.1016\/j.beha.2019.101097","article-title":"Chimeric antigen receptor T cells (CAR-T) for the treatment of T-cell malignancies","volume":"32","author":"Cooper","year":"2019","journal-title":"Best Pract Res Clin Haematol"},{"key":"10.1016\/j.clml.2022.07.010_bib0085","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1186\/s13045-019-0801-y","article-title":"Targeting T cell malignancies using CAR-based immunotherapy: challenges and potential solutions","volume":"12","author":"Fleischer","year":"2019","journal-title":"J Hematol & Oncol"},{"key":"10.1016\/j.clml.2022.07.010_bib0086","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/s40364-022-00352-w","article-title":"Haploidentical CD7 CAR T-cells induced remission in a patient with TP53 mutated relapsed and refractory early T-cell precursor lymphoblastic leukemia\/lymphoma","volume":"10","author":"Dai","year":"2022","journal-title":"Biomarker Res"},{"key":"10.1016\/j.clml.2022.07.010_bib0087","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1158\/1078-0432.CCR-20-1271","article-title":"Eradication of T-ALL Cells by CD7-targeted Universal CAR-T Cells and Initial Test of Ruxolitinib-based CRS Management","volume":"27","author":"Li","year":"2021","journal-title":"Clin Can Res"},{"key":"10.1016\/j.clml.2022.07.010_bib0088","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2021.107731","article-title":"Chimeric antigen receptor T cells targeting CD7 in a child with high-risk T-cell acute lymphoblastic leukemia","volume":"96","author":"Xie","year":"2021","journal-title":"Int Immunopharmacol"},{"key":"10.1016\/j.clml.2022.07.010_bib0089","doi-asserted-by":"crossref","first-page":"3340","DOI":"10.1200\/JCO.21.00389","article-title":"Donor-derived CD7 chimeric antigen receptor T-Cells for T-Cell acute lymphoblastic leukemia: first-in-human, phase I trial","volume":"39","author":"Pan","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2022.07.010_bib0090","doi-asserted-by":"crossref","first-page":"7035","DOI":"10.1200\/JCO.2022.40.16_suppl.7035","article-title":"Autologous CD7-targeted CAR T-cell therapy for refractory or relapsed T-cell acute lymphoblastic leukemia\/lymphoma","volume":"40","author":"Zhao","year":"2022","journal-title":"J Clin Oncol"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265022002300?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265022002300?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,10,25]],"date-time":"2024-10-25T11:47:34Z","timestamp":1729856854000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265022002300"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10]]},"references-count":90,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2022,10]]}},"alternative-id":["S2152265022002300"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2022.07.010","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2022,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"SOHO State of the Art Updates and Next Questions | Novel Approaches to Pediatric T-cell ALL and T-Lymphoblastic Lymphoma","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2022.07.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}